15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Cytek Biosciences Inc, 3 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $4.75 to $7.50, a moderate spread. The average target of $5.69 sits 29% above the current $4.42. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.03 next quarter toward $0.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy375%
Hold125%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Cytek Biosciences Inc.
As of Jul, 3 of 4 firms rate CTKB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CTKB EPS & revenue forecast
EPS · NEXT QUARTER
$0.03
Range $0.03 – $0.03 · 1 analysts · -10100% YoY
Next period, 1 analysts expect Cytek Biosciences Inc to earn $0.03 a share (range $0.03 – $0.03), versus $-0.00 a year earlier. Full-year consensus is $-0.03, growing to $0.20 the year after.
REVENUE · NEXT QUARTER
$55.2M
Range $53.8M – $57.3M · 1 analysts · +5% YoY
Revenue is expected to reach $55.2M (range $53.8M – $57.3M), +5.5% year-over-year. Full-year consensus is $208.8M, rising to $222.7M next year.
Top analysts covering Cytek Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTKB.
#1
Matthew Sykes
Goldman Sachs · Rank #226
Sell
$3.00-32.1% to target
Overall win rate
37%
+ Follow
#2
David Westenberg
Piper Sandler · Rank #227
Buy
$7.50+69.7% to target
Overall win rate
31%
+ Follow
#3
MC
Mason Carrico
Stephens & Co.
Buy
$4.75+7.5% to target
Coverage
—
+ Follow
#4
TS
Tejas Savant
Morgan Stanley
Hold
$5.50+24.4% to target
Coverage
—
+ Follow
#5
BS
Brendan Smith
TD Cowen
Buy
$5.00+13.1% to target
Coverage
—
+ Follow
CTKB stock forecast FAQ
What is CTKB's average 12-month price target?+
The 4 analysts with a live target average $5.69 for Cytek Biosciences Inc over the next 12 months, ranging from a $7.50 high to a $4.75 low.
Is CTKB stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 3 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CTKB?+
The Street-high target is $7.50 (Piper Sandler), and the Street-low is $4.75 (Stephens & Co.). The average of all 4 active targets is $5.69.
How many Wall Street analysts cover CTKB?+
4 analysts have an active rating on Cytek Biosciences Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering CTKB?+
Among analysts who currently cover CTKB, Matthew Sykes of Goldman Sachs has the strongest overall Quantellect track record (Rank #226). Their current call is Sell with a $3.00 target.
What is Cytek Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $0.03 per share (range $0.03 – $0.03) across 1 analysts. Full-year EPS is projected at $-0.03, rising to $0.20 the following year.
How much revenue is Cytek Biosciences Inc expected to report next quarter?+
Consensus revenue is $55.2M (range $53.8M – $57.3M). Full-year revenue is projected at $208.8M, growing to $222.7M next year.
Have analysts been upgrading or downgrading CTKB lately?+
As of Jul, 3 of 4 firms rate CTKB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTKB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
